In the wake of Covid-19, psychedelic-assisted therapy is gaining attention.
The first trial will determine the sublingual dose equivalent to 25 mg psilocybin administered orally.
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
Recent research suggests that psilocybin causes changes in amygdala activity opposite to those seen in conventional antidepressant treatment.
After 4.5 years, 60-80% of the study participants with life-threatening cancer still experienced significantly decreased anxiety or antidepressant effects.
Some changes occured to biomarkers for stress and inflammation. The subjective effects reveal more evidence of the entourage effect.